Tag Archive for: bispecific antibody

AM109: A PSMA‑Targeted CD137 Bispecific Antibody for Metastatic Castration‑Resistant Prostate Cancer (mCRPC / mAPMR)

/in , /by

AM109 is designed as a bispecific agent that links a PSMA‑targeting humanized antibody to a CD137 (4‑1BB)‑targeting affibody, effectively creating a molecular bridge between prostate cancer cells and T cells in the tumor microenvironment. The rationale is straightforward: by restricting CD137 activation to sites where PSMA is expressed, the therapy aims to drive potent anti‑tumor […]

Read more

APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer

/in , /by

A Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]

Read more